1. Home
  2. CANF vs GOVX Comparison

CANF vs GOVX Comparison

Compare CANF & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Can-Fite Biopharma Ltd Sponsored ADR (Israel)

CANF

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

HOLD

Current Price

$3.24

Market Cap

4.7M

Sector

Health Care

ML Signal

HOLD

Logo GeoVax Labs Inc.

GOVX

GeoVax Labs Inc.

HOLD

Current Price

$1.53

Market Cap

4.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CANF
GOVX
Founded
1994
2001
Country
Israel
United States
Employees
N/A
17
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.7M
4.0M
IPO Year
2011
N/A

Fundamental Metrics

Financial Performance
Metric
CANF
GOVX
Price
$3.24
$1.53
Analyst Decision
Strong Buy
Buy
Analyst Count
2
2
Target Price
$9,750.00
$200.00
AVG Volume (30 Days)
612.1K
62.0K
Earning Date
03-27-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$461.72
N/A
Revenue Next Year
$290,391.28
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.17
$0.12
52 Week High
$10.40
$4.40

Technical Indicators

Market Signals
Indicator
CANF
GOVX
Relative Strength Index (RSI) 36.09 40.07
Support Level $0.63 $1.49
Resistance Level $4.74 $4.40
Average True Range (ATR) 0.24 0.16
MACD -0.13 -0.01
Stochastic Oscillator 3.03 26.87

Price Performance

Historical Comparison
CANF
GOVX

About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.

About GOVX GeoVax Labs Inc.

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.

Share on Social Networks: